What Makary’s Plan For Expanding OTC Drug Access Could Mean For Safety

Why It Matters

Broad OTC access could improve patient convenience and public health outcomes, but careless expansion—especially for antibiotics—risks accelerating drug‑resistant infections worldwide.

Key Takeaways

• Makary advocates OTC for all safe, non‑addictive drugs.
• OTC contraceptives could lower unintended pregnancy rates.
• Antibiotic OTC availability risks accelerating antimicrobial resistance.
• Pharmacist‑prescribed antibiotics may balance access and stewardship.
• US withdrawal from WHO hinders coordinated OTC safety efforts.

Pulse Analysis

Marty Makary’s push for a sweeping over‑the‑counter (OTC) drug policy reflects a growing sentiment that regulatory gatekeeping often delays care. By pointing to low‑risk products such as acetaminophen, ibuprofen, and certain hormonal contraceptives, he argues that removing prescription barriers can increase adherence, reduce unintended pregnancies, and empower consumers. The FDA’s risk‑evaluation framework would still apply to substances with abuse potential or serious side‑effects, preserving safety nets while modernising access. This perspective aligns with global trends where more than 100 nations already sell combined estrogen‑progestin pills without a prescription.

The proposal, however, collides with a stark public‑health dilemma: antimicrobial resistance (AMR). Data from the CDC show over 2.8 million AMR infections and 35,000 deaths annually in the United States, a figure that could surge if antibiotics become freely available. Studies from India and Europe demonstrate that unsupervised antibiotic use fuels resistant strains like NDM‑CRE, which are difficult and costly to treat. The risk of sub‑therapeutic dosing, a concern raised by Alexander Fleming, underscores why stewardship remains essential even as access improves.

A pragmatic compromise may lie in expanding the role of trained pharmacists and point‑of‑care diagnostics. Allowing pharmacists to prescribe for uncomplicated infections—supported by rapid strep or urine tests—could preserve rapid access while curbing misuse. Such models have shown promise in reducing unnecessary prescriptions in several European countries. Yet the United States’ recent withdrawal from WHO collaborations hampers coordinated global responses to OTC misuse. Re‑engaging with international health bodies and investing in universal primary‑care coverage would strengthen the infrastructure needed to balance accessibility with safety, ensuring Makary’s vision does not inadvertently trigger a post‑antibiotic crisis.